Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura.
Benedetti
Luana
L
Franciotta
Diego
D
Beronio
Alessandro
A
Cadenotti
Luigi
L
Gobbi
Marco
M
Mancardi
Giovanni Luigi
GL
Schenone
Angelo
A
Tartaglione
Antonio
A
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D004558:Electric Stimulation / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000150:complications / Q000188:drug therapy*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab